Debt-to-equity of TScan Therapeutics, Inc. from 31 Mar 2022 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: TScan Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 31 Dec 2025.
TScan Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 72%, a 25% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

TScan Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	72%	+14%	+25%	31 Dec 2025
Q3 2025	64%	+0.82%	+1.3%	30 Sep 2025
Q2 2025	58%	-11%	-16%	30 Jun 2025
Q1 2025	53%	-25%	-32%	31 Mar 2025
Q4 2024	57%	-22%	-27%	31 Dec 2024
Q3 2024	63%	-20%	-24%	30 Sep 2024
Q2 2024	69%	-7.5%	-9.8%	30 Jun 2024
Q1 2024	77%	+15%	+24%	31 Mar 2024
Q4 2023	79%	+40%	+104%	31 Dec 2023
Q3 2023	83%	+61%	+284%	30 Sep 2023
Q2 2023	76%	+60%	+361%	30 Jun 2023
Q1 2023	62%	+36%	+135%	31 Mar 2023
Q4 2022	39%			31 Dec 2022
Q3 2022	22%			30 Sep 2022
Q2 2022	17%			30 Jun 2022
Q1 2022	26%			31 Mar 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.